Company Introduction

Teclison is a clinical-stage biotech company founded by prior veterans of Roche and Merck since 2013. We have three assets that not only kill tumor but also convert tumor into a therapeutic vaccine. Our leading pipeline is a first-in-class compound that has completed a phase 2 clinical study and improves efficacy anti-PD-1 in metastatic liver cancer, notably in metastatic colorectal cancer, the number two cancer with multi-billion-dollar market. We collaborate with Merck for further development. Teclison seeks series B $75M equity investment to support clinical studies in mCRC and liver cancer, aiming to market approval in 3 years.

Brief description of main products or services 

Teclison’s pipeline product is designed to solve the problem of poor efficacy of immunotherapy in solid tumor with liver metastasis. A notable example is mCRC, which is refractory to anti-PD-(L)1.  Teclison developed a first-in-class hypoxia-activating agent, which generates free radical in the hypoxia environment to induce tumor necrosis, a type of immunogenic cell death. This approach kills two birds with one stone, by effectively elimination of liver lesion, and conversion of liver lesion into a therapeutic vaccine that greatly enhances the efficacy of immunotherapy. The treatment is well tolerated due to the reason that systemic organs have no hypoxia to activate the compound to cause any systemic toxicity or immunosuppression. Our pipeline product in combination with Keytruda has achieved proof-of-concept in refractory mCRC-MSS who have failed standard chemotherapy. Compared with historically 1-2% overall response rate (ORR), median OS 6-7 months, our product plus Keytruda achieved an ORR of 36% and median OS of 16.5 months. Liver cancer and mCRC-MSS will be the top indications for fast market approval in 3 years. The same strategy will be expanded to all solid tumors with liver metastasis to gain a huge market.